Navigation Links
Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
Date:12/13/2007

RALEIGH, N.C., Dec. 13 /PRNewswire/ -- The most recent study from the landmark Framingham trial demonstrates the clinical significance of knowing the number of LDL particles (LDL-P) by NMR in the management of a patient's risk for heart disease. This longitudinal outcomes study shows that low levels of LDL particles are associated with fewer cardiovascular disease (CVD) related events than equivalently low levels of LDL cholesterol. The findings confirm that low levels of LDL cholesterol may have limitations and suggests that managing patients to LDL-P targets of therapy may improve patient outcomes.

The NMR LipoProfile test, developed by LipoScience, Inc., is the only test that quantifies the number of LDL particles (LDL-P). LDL particle information is used by clinicians to better manage a patient's cardiovascular health by lowering the number of LDL particles (LDL-P) to acceptable levels using familiar LDL lowering therapies.

Authors, William C. Cromwell, MD, et al, compared the relative ability of LDL cholesterol (LDL-C) and the number of LDL particles (LDL-P), two alternative measures of LDL, to predict cardiovascular disease events at low levels. The study found low numbers of LDL particles, as measured by the NMR LipoProfile test, to be associated with 27% fewer cardiovascular disease events than equivalently low levels of LDL cholesterol. This suggests a clinical role for LDL-P as a treatment target for LDL management.

The authors concluded that because the cholesterol content of LDL particles between individuals is highly variable, LDL cholesterol levels often underestimate the number of LDL particles and a patient's risk for heart disease. In fact, data from another Framingham population showed that 50% of individuals who suffered a heart attack had normal LDL cholesterol levels. Many patients who are being managed to LDL-C targets of therapy, as established by current guidelines, are still at significant risk for cardiovascular disease (CVD). In this study, LDL-P was shown to be a more sensitive indicator of low CVD risk than LDL-C or non-HDL-C, another potential treatment target. The study reinforces the limitations of LDL cholesterol and the importance of managing patients to acceptably low levels of LDL-P to avoid CVD related events such as heart attack.

Data in over 100 published papers reinforce the superior clinical value of the NMR LipoProfile test. These most recent findings were published in the National Lipid Association's December issue of Journal of Clinical Lipidology.

(1) William C. Cromwell, MD, James D. Otvos, PhD et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. J Clin Lipidology 2007; 1: 583-592.


'/>"/>
SOURCE LipoScience, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
4. Sports Legacy Institute Announces Findings of Forensic Examinations on Wrestler Chris Benoits Brain
5. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
6. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
10. Top Washington Health Officials to Honor Framingham Heart Study Participants
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017  BERG, a biopharmaceutical company ... research approach, today announced that the company,s ... of new data using a cold-induced model ... metabolism. Joslin Diabetes Center led the investigation ... for analysis of samples.  The findings were ...
(Date:3/27/2017)... March 27, 2017 On Friday, ... NASDAQ Composite closed the trading session up 0.19%; the ... S&P 500 was down 0.08%. US markets made broad ... the day in green. Pre-market today, Stock-Callers.com reviews these ... N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group ...
(Date:3/27/2017)... BOSTON , March 27, 2017  Allergan ... and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical ... innovative therapies based upon tetracycline chemistry, announced that ... the treatment of moderate to severe acne met ... a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... A minimally ... the “perfect smile.” The National Association of Dental Laboratories (NADL) is informing dentists ... be aware of when utilizing dental laboratories and technicians that create these veneers. ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice Treatment Center® booth ... 13-16, was a busy spot this year. Liz Solovay and Adrian Picheny, the ... outbreaks among camp communities during the upcoming 2017 camping season. “Lice infestations at ...
(Date:3/28/2017)... ... 2017 , ... Thank you to all who attended Capio Partners Winter 2017 ... was exclusive to providers and offered an opportunity to collaborate and network with healthcare ... Grand Hyatt where attendees gathered for a lively discussion on trends and issues that ...
(Date:3/27/2017)... ... ... New patients who have sleep apnea in Aurora, CO, can now ... Sleep apnea is often left untreated because patients are not familiar with common symptoms ... , Dr. Braasch seeks to raise awareness of sleep apnea in Aurora, CO, and ...
(Date:3/27/2017)... ... March 27, 2017 , ... Drs. Justin Kolnick, Kara ... by teaching their patients about the key role this treatment plays in protecting oral ... experienced endodontist. To better serve those who need a root canal in White Plains, ...
Breaking Medicine News(10 mins):